CY1112906T1 - Αναστολεις διαυλου νατριου - Google Patents

Αναστολεις διαυλου νατριου

Info

Publication number
CY1112906T1
CY1112906T1 CY20111101095T CY111101095T CY1112906T1 CY 1112906 T1 CY1112906 T1 CY 1112906T1 CY 20111101095 T CY20111101095 T CY 20111101095T CY 111101095 T CY111101095 T CY 111101095T CY 1112906 T1 CY1112906 T1 CY 1112906T1
Authority
CY
Cyprus
Prior art keywords
sodium channel
suspensions
present
channel blockers
variety
Prior art date
Application number
CY20111101095T
Other languages
English (en)
Inventor
Michael R Johnson
Original Assignee
Parion Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27752677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Parion Sciences, Inc. filed Critical Parion Sciences, Inc.
Publication of CY1112906T1 publication Critical patent/CY1112906T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32—(Amino-pyrazinoyl) guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά αναστολείς διαύλου νατρίου. Η παρούσα εφεύρεση περιλαμβάνει επίσης ποικιλία μεθόδων θεραπείας χρησιμοποιώντας αυτούς τους εφευρετικούς αναστολείς διαύλου νατρίου.
CY20111101095T 2002-02-19 2011-11-14 Αναστολεις διαυλου νατριου CY1112906T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/076,571 US6858615B2 (en) 2002-02-19 2002-02-19 Phenyl guanidine sodium channel blockers
EP03742810A EP1485360B1 (en) 2002-02-19 2003-02-19 Sodium channel blockers

Publications (1)

Publication Number Publication Date
CY1112906T1 true CY1112906T1 (el) 2016-04-13

Family

ID=27752677

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101095T CY1112906T1 (el) 2002-02-19 2011-11-14 Αναστολεις διαυλου νατριου

Country Status (14)

Country Link
US (15) US6858615B2 (el)
EP (1) EP1485360B1 (el)
JP (2) JP4557550B2 (el)
KR (3) KR101225201B1 (el)
AT (1) ATE520674T1 (el)
AU (2) AU2003211135B2 (el)
CA (1) CA2476430C (el)
CY (1) CY1112906T1 (el)
DK (1) DK1485360T3 (el)
ES (1) ES2374130T3 (el)
HK (1) HK1070369A1 (el)
PT (1) PT1485360E (el)
SI (1) SI1485360T1 (el)
WO (1) WO2003070182A2 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2004264441A1 (en) * 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
PT1663235E (pt) * 2003-08-18 2013-10-29 Parion Sciences Inc Novos bloqueadores dos canais do sódio de pirazinoílguanidina protegida
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
JP2007502827A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
JP4632048B2 (ja) * 2003-11-19 2011-02-16 ライオン株式会社 唾液分泌促進剤
GB0403864D0 (en) * 2004-02-20 2004-03-24 Ucl Ventures Modulator
CA2575670A1 (en) * 2004-08-18 2006-03-02 Michael R. Johnson Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US8143256B2 (en) 2004-08-18 2012-03-27 Parion Sciences, Inc. Cyclic amide and ester pyrazinoylguanidine sodium channel blockers
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
AU2012201188B2 (en) * 2005-08-03 2013-02-07 Parion Sciences, Inc. New capped pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) * 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
DK2035004T3 (en) * 2006-06-09 2013-01-02 Parion Sciences Inc Phenylsubstituerede pyrazinoylguanidin-natriumkanalblokkere med beta-agonistaktivitet
CA2653773A1 (en) * 2006-06-09 2007-12-21 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
WO2007146867A2 (en) * 2006-06-09 2007-12-21 Parion Sciences Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
TW200819430A (en) * 2006-09-07 2008-05-01 Michael R Johnson Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
MX2009002602A (es) * 2006-09-07 2009-05-28 Parion Sciences Inc Metodos para aumentar la hidratacion mucosa y el despeje mucoso mediante tratamiento con bloqueadores de canal de sodio y osmolitos.
EP1939173A1 (en) * 2006-12-21 2008-07-02 Pharmeste S.r.l. O-substituted-dibenzyl urea- or thiourea- derivatives as trpv1 receptor antagonists
US20080293740A1 (en) * 2007-04-03 2008-11-27 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders
WO2008124491A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
EP2231280B1 (en) * 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
NZ586940A (en) 2008-02-26 2012-08-31 Parion Sciences Inc Poly aromatic sodium channel blocker compounds comprising both pyrazine and guanidine moieties
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
WO2011156355A1 (en) * 2010-06-09 2011-12-15 Kainos Medicine, Inc. Production method of phenyl guanidine salts and their intermediates
CA2819635A1 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AU2012267938B2 (en) 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
US9072738B2 (en) 2011-06-27 2015-07-07 Parion Sciences, Inc. Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
TR201809148T4 (tr) 2012-05-29 2018-07-23 Parion Sciences Inc Göz kuruluğu ve diğer mukozal hastalıkların tedavisi için sodyum kanal blokör etkinliğine sahip dendrimer benzeri amino asitler.
KR20150095870A (ko) * 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
ES2674665T3 (es) * 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
EP3022196B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel benzimidazolium compounds
MX368243B (es) 2013-08-23 2019-09-25 Parion Sciences Inc Agentes mucolíticos de ditiol.
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
UY36034A (es) 2014-03-18 2015-09-30 Astrazeneca Ab Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
EP3250548A4 (en) 2015-01-30 2018-07-11 Parion Sciences, Inc. Novel monothiol mucolytic agents
EP3244893A4 (en) * 2015-02-18 2019-01-09 Parion Sciences, Inc. SODIUM CHANNEL BLOCKER FOR SKIN DISEASES
CN107708680A (zh) 2015-04-30 2018-02-16 帕里昂科学公司 新的二硫醇粘液溶解剂的前药
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds

Family Cites Families (350)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268406A (en) 1961-10-12 1966-08-23 Merck & Co Inc Compositions and method of using (3-amino-pyrazinoyl) guanidines
BE639393A (el) 1962-10-30
NL6409716A (el) 1962-10-30 1965-10-01
DK109779C (da) 1962-10-30 1968-07-01 Merck & Co Inc Fremgangsmåde til fremstilling af 3-aminopyrazinamidoguanidinforbindelser eller syreadditionssalte heraf.
NL299931A (el) 1962-10-30
US3316266A (en) 1964-03-31 1967-04-25 Merck & Co Inc 3-aminopyrazinoic acid derivatives and process for their preparation
NL6409714A (el) 1962-10-30 1965-10-01
US3274191A (en) 1963-11-15 1966-09-20 Merck & Co Inc N-(3-aminopyrazinoyl) benzamidines and process for preparing
US3240780A (en) 1963-12-23 1966-03-15 Merck & Co Inc Amino-pyrazinoyl guanidines
DE1245967B (de) 1964-03-31 1967-08-03 Merck &. Co., Inc., Rahway, N.J. (V. St. A.) Verfahren zur Herstellung von S.S-Diamino-o-chlor-pyrazincarbonsäurealkylestern
NL6501301A (el) 1964-04-03 1965-10-04
US3249610A (en) 1964-09-08 1966-05-03 Merck & Co Inc Synthesis of 3-amino, 5-chloro, 6-substituted-pyrazinoates
DE1281818B (de) 1965-07-17 1968-10-31 Rheinische Kalksteinwerke Verfahren zum gleichzeitigen Mahlen mehrerer Rohstoffe unterschiedlicher Mahlbarkeit
US3274192A (en) 1965-10-04 1966-09-20 Merck & Co Inc Derivatives of pyrazine and a method for their preparation
US3341540A (en) 1965-10-04 1967-09-12 Merck & Co Inc 3-amino-6-halopyrazinonitriles and their syntheses
US3305552A (en) 1965-11-22 1967-02-21 Merck & Co Inc 3-aminopyrazinoic acids and process for their preparation
US3361748A (en) 1965-11-22 1968-01-02 Merck & Co Inc Process for the preparation of pteridinones
FR1525671A (fr) 1966-08-25 1968-05-17 Merck & Co Inc Procédé de préparation de (3, 5 - diamino - 6 - halogéno - pyrazinoyl) - guanidines et de (3, 5 - diamino - 6 - halogéno -pyrazinamido) guanidines
NL6707564A (el) 1966-08-25 1968-02-26
IL27897A (en) 1966-08-25 1972-02-29 Merck & Co Inc Preparation of pyrazinoalguanides and pyrazinoamidoguanidines
FR1525670A (fr) 1966-08-25 1968-05-17 Merck & Co Inc Procédé de fabrication de guanidines substituées
US3660400A (en) 1966-11-17 1972-05-02 Merck & Co Inc Lower alkyl 3-hydroxy and 3-mercaptopyrazinoates
US3472848A (en) 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3527758A (en) 1967-04-13 1970-09-08 Merck & Co Inc Process for the preparation of pyrazinoylguanidines from a pyrazinoic azide and a guanidine
US3507865A (en) 1967-04-27 1970-04-21 Merck & Co Inc 3-hydroxy- and 3-mercaptopyrazinamidoguanidines the corresponding ethers and thioethers and processes for their preparation
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3487082A (en) 1967-09-28 1969-12-30 Merck & Co Inc 2,4 - diamino - 6 - halopteridines and processes for their preparation
US3503973A (en) 1967-11-07 1970-03-31 Merck & Co Inc Process for preparation of pyrazinoylguanidines
US3515723A (en) 1967-11-14 1970-06-02 Merck & Co Inc 2 - (5 - amino - 1h - 1,2,4 - triazol - 3 - yl)- 3-aminopyrazines and processes for their preparation
US3531484A (en) 1968-02-14 1970-09-29 Merck & Co Inc 1-(3-aminopyrazinoyl)-4,5,5-trisubstituted biguanide products
US3461123A (en) 1968-04-12 1969-08-12 Merck & Co Inc 1h-imidazo(4,5-b)pyrazin-2-ones and processes for their preparation
US3506662A (en) 1968-04-30 1970-04-14 Merck & Co Inc Process for preparation of pyrazinoyland pyrazinamidoguanidines
US3625950A (en) 1968-07-03 1971-12-07 Merck & Co Inc Certain halophenoxy alkanamides, hydrazides and derivatives thereof
US3575975A (en) 1968-07-25 1971-04-20 Merck & Co Inc Process for the preparation of 3-aminopyrazinoylureas
US3539569A (en) * 1968-08-21 1970-11-10 Merck & Co Inc Preparation of pyrazinoylguanidines from pyrazinoylureas
US3544571A (en) 1968-09-04 1970-12-01 Merck & Co Inc Process for making pyrazinoylthiourea compounds
US3555024A (en) 1968-11-13 1971-01-12 Merck & Co Inc 1-(3-aminopyrazinoyl)semicarbazides,1-(3-aminopyrazinoyl) - thiosemicarbazides,and method for their preparation
US3555023A (en) 1968-11-13 1971-01-12 Merck & Co Inc 1-(3 - aminopyrazinoyl) - 3 - substituted-3-thioisosemicarbazides and method for preparation
US3668241A (en) 1968-11-25 1972-06-06 Merck & Co Inc Substituted 1-oxoinden-5-yloxy alkanoic acids
US3586688A (en) 1968-12-18 1971-06-22 Merck & Co Inc Certain aminopyridinecarbonyl guanidines
US3573305A (en) 1968-12-30 1971-03-30 Merck & Co Inc (3-amino-pyrazinoyl)sulfamides and their preparation
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) * 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
US3544568A (en) 1969-03-18 1970-12-01 Merck & Co Inc 3-amino-5,6-substituted pyrazinamides
US3660397A (en) 1970-04-17 1972-05-02 Merck & Co Inc Imidazo(4 5-b)pyrazines
US3864401A (en) 1970-12-23 1975-02-04 Merck & Co Inc Substituted 2-aminomethyl-4,6-dihalophenols
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US3935313A (en) 1971-03-29 1976-01-27 Jan Marcel Didier Aron-Samuel Pharmaceutical composition containing N-(3-diethyl-aminopropyl)-4-nitro-1-oxide-pyridine-2-carboxamide and process for the treatment of hypertension therewith
US3948895A (en) 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
BE791201A (fr) 1971-11-12 1973-05-10 Merck & Co Inc Indanyloxytetrazoles
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
US3894085A (en) 1972-09-19 1975-07-08 Ciba Geigy Corp New 2-halo nitrones, their manufacture and their use for the manufacture of N-substituted araliphatic aldehyde-nitrones
US4085219A (en) 1972-10-13 1978-04-18 Merck & Co., Inc. 1-Oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids
US3976686A (en) 1972-10-13 1976-08-24 Merck & Co., Inc. [1-Oxo-2,3-hydrocarbylene-5-indanyloxy(or thio)]alkanoic acids
US3984465A (en) 1972-10-13 1976-10-05 Merck & Co., Inc. 1-Oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids
US4081554A (en) 1972-10-13 1978-03-28 Merck & Co., Inc. 1-oxo-2,2-disubstituted-5-indanyloxy(or thio)alkano acids
US4091015A (en) 1972-10-27 1978-05-23 American Home Products Corporation 15-Substituted prostanoic acids
US4066692A (en) 1972-10-30 1978-01-03 Merck & Co., Inc. 11,12-secoprostaglandins
US4092356A (en) 1972-10-30 1978-05-30 Merck & Co., Inc. 11,12-Secoprostaglandins
US4055597A (en) 1973-01-26 1977-10-25 Merck & Co., Inc. 10-Aza-11,12-secoprostaglandins
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US4091107A (en) 1973-04-25 1978-05-23 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US3894065A (en) 1973-04-27 1975-07-08 Merck & Co Inc Aryl-oxo-alkanoic acids
US4182764A (en) 1973-10-11 1980-01-08 Merck & Co., Inc. Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids
US4177285A (en) 1973-10-11 1979-12-04 Merck & Co., Inc. [1-Oxo-2-thienyl-2-substituted-5-indanyloxy (or thio)]alkanoic acids and derivatives thereof
US4006180A (en) 1973-10-12 1977-02-01 Merck & Co., Inc. [1,3-Dihydroxy-2-substituted and 2,2-disubstituted-indanyloxy(or thio)]alkanoic acids
US4012524A (en) 1973-10-12 1977-03-15 Merck & Co., Inc. [1-Hydroxy-5-indanyloxy (or thio)]-alkanoic acids
US3976681A (en) 1973-10-12 1976-08-24 Merck & Co., Inc. [1,3-Dioxo-2-substituted and 2,2-disubstituted- indanyloxy (or thio] alkanoic acids
US3929872A (en) 1973-10-12 1975-12-30 Merck & Co Inc Indanacetic acid compounds
US3966966A (en) 1973-10-12 1976-06-29 Merck & Co., Inc. Pharmaceutical compositions and method of treatment employing 1,3-dioxo-2,2-disubstituted indanyloxy alkanoic acids
US4003927A (en) 1973-10-12 1977-01-18 Merck & Co., Inc. (1-Oxo-7,8-disubstituted-1,2,3,4-tetrahydro-6-naphthyloxy)- and (3,4-disubstituted-5-oxo-6,7,8,9-tetrahydro-5H-benzocycloheptene-2-yloxy) acetic acids and derivatives
US3989749A (en) 1973-10-17 1976-11-02 Merck & Co., Inc. 11,12-Secoprostaglandins
US3991087A (en) 1973-12-13 1976-11-09 Merck & Co., Inc. 8-Halo-11,12-secoprostaglandins
US3979361A (en) 1974-02-20 1976-09-07 Merck & Co., Inc. 2-Aminomethyl-6-trihalo-methylphenols
US3914253A (en) 1974-03-04 1975-10-21 Merck & Co Inc 5-Oxo-6-substituted-cyclopent-{8 f{9 -indole-2-carboxylic acids
US3931239A (en) 1974-04-03 1976-01-06 Merck & Co., Inc. 6-Oxo-7-substituted-6H-indeno-[5,4-b]furan(and thiophene)-carboxylic acids
US3958004A (en) 1974-04-23 1976-05-18 Merck & Co., Inc. Phenoxyacetic acid derivatives as uricosuric agents
US3928624A (en) 1974-04-25 1975-12-23 Merck & Co Inc Phenol compounds in treating pain, fever and inflammation
US3956374A (en) 1974-05-03 1976-05-11 Merck & Co., Inc. Aryl-oxo-heptenoic acids
US3974212A (en) 1974-05-22 1976-08-10 Merck & Co., Inc. [1-Hydroximino-2,2-disubstituted-5-indanyloxy-(or thio)]alkanoic acids
AT351182B (de) 1974-06-25 1979-07-10 Merck & Co Inc Verfahren zur herstellung von neuen 9-thia-, 9-oxothia- und 9-dioxothia- 11,12-secoprosta- glandinen
PL98342B1 (pl) 1974-07-30 1978-04-29 Sposob wytwarzania kwasu 1-keto-2-arylo-/lub tienylo/-2-podstawionego-indanyloksy-/lub tio/-5-alkanokarboksylowego
US4020177A (en) 1974-08-30 1977-04-26 Merck & Co., Inc. Substituted phenoxy-tridecanoic acids
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3984552A (en) 1975-02-24 1976-10-05 Merck & Co., Inc. 6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids
JPS51116341A (en) 1975-04-04 1976-10-13 Automob Antipollut & Saf Res Center Detection apparatus for oil pressure
US4018802A (en) 1975-04-09 1977-04-19 Merck & Co., Inc. 9-Thia- and oxothia- and 9-dioxothia-11,12-seco-prostaglandins and processes
US4097504A (en) 1975-04-23 1978-06-27 Merck & Co., Inc. 11,12-Secoprostaglandins
US4092414A (en) 1975-04-25 1978-05-30 Merck & Co., Inc. 3,4-Dihydrospiro-2H-1,3-benzoxazines and their use in treating edema, abnormal electrolyte retention, and inflammation
US4059602A (en) 1975-06-06 1977-11-22 Merck & Co., Inc. 8-Methyl-, phenyl-, or substituted phenyl-11,12-secoprostaglandins
US4059601A (en) 1975-06-06 1977-11-22 Merck & Co., Inc. 8-Halo-11,12-secoprostaglandins
US4126629A (en) 1975-06-18 1978-11-21 Merck & Co., Inc. Substituted phenoxy-tridecenoic acids/esters
US4087542A (en) 1975-07-09 1978-05-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-acyl benzofuran-2-carboxylic acids
US4296122A (en) 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
US4181727A (en) 1975-07-09 1980-01-01 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-acyl benzofuran-2-carboxylic acids
US4044153A (en) 1975-08-01 1977-08-23 Merck & Co., Inc. Antiinflammatory 2-aminomethyl-6-trihalomethylphenols
US4203988A (en) 1975-11-12 1980-05-20 Merck & Co., Inc. Pyridinyl ureas and pharmaceutical use
US4029816A (en) 1975-11-25 1977-06-14 Merck & Co., Inc. Substituted 2-aminomethyl-6-iodophenols
US4085211A (en) 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4070464A (en) 1976-02-19 1978-01-24 Merck & Co., Inc. Method of treating autoimmune diseases
US4128564A (en) 1976-03-22 1978-12-05 Merck & Co., Inc. 9-Thia- and oxothia- and 9-dioxothia-11,12-seco-prostaglandins
US4085125A (en) 1976-03-22 1978-04-18 Merck & Co., Inc. 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes
US4181661A (en) 1976-05-03 1980-01-01 Merck & Co., Inc. Derivatives of 2-iminothiazolidines and thiazolines
US4029803A (en) 1976-05-03 1977-06-14 Merck & Co., Inc. Method of treatment with 2-iminothiazolidines and thiazolines
US4059587A (en) 1976-05-24 1977-11-22 Merck & Co., Inc. Certain thiazolidine compounds
US4022794A (en) 1976-05-24 1977-05-10 Merck & Co., Inc. Novel analogs of prostaglandins with 4-oxo-thiazolidinyl nucleus and method of preparation thereof
NL7705652A (nl) 1976-06-15 1977-12-19 Merck & Co Inc 2-imino-3-aminothiazolidinen.
US4054652A (en) 1976-06-15 1977-10-18 Merck & Co., Inc. Dihydro- and tetrahydro- iminothiazines
US4025625A (en) 1976-06-15 1977-05-24 Merck & Co., Inc. Imidazothiazines
US4087526A (en) 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4111877A (en) 1976-07-29 1978-09-05 Air Products & Chemicals, Inc. Allyl esters of n-alkyl-omega-(alkyleneureido) amic acids and their synthesis and use in aqueous emulsion polymer systems
US4067980A (en) 1976-08-16 1978-01-10 Merck & Co., Inc. Spirobenzoxazinium salts, method of use and compositions thereof as antihypertensive agents
US4085117A (en) 1976-10-18 1978-04-18 Merck & Co., Inc. 6,7-Disubstituted-5-(acyl)benzofuran-2-carboxylic acids
US4100294A (en) 1976-12-06 1978-07-11 Merck & Co., Inc. 5-(Hydroxy (substituted) methyl)-2,3-dihydrobenzo furan-2-carboxylic acid and its derivatives
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4150235A (en) 1976-12-17 1979-04-17 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4105769A (en) 1977-01-24 1978-08-08 Merck & Co., Inc. Inhibition of indoleamine-N-methyl transferase by 2-iminopyridines
US4087435A (en) 1977-02-17 1978-05-02 Merck & Co., Inc. 8-Aza-9-dioxothiaprostanoic acids
US4115573A (en) 1977-03-04 1978-09-19 Merck & Co., Inc. N-pyrazinecarbonyl-N'-substituted-sulfamoylguanidine and processes for preparing same
US4208413A (en) 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4108859A (en) 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4115402A (en) 1977-06-17 1978-09-19 Merck & Co., Inc. 2,3-Dichloro-4-[(substituted-sulfonyl)-phenoxy]-acetic acids
US4196292A (en) 1977-06-29 1980-04-01 Merck & Co., Inc. 6-Substituted amiloride derivatives
US4133885A (en) 1977-07-18 1979-01-09 Merck & Co., Inc. Substituted naphthyridinones
US4229456A (en) 1977-07-18 1980-10-21 Merck & Co., Inc. Substituted naphthyridinones and processes for their preparations
US4536507A (en) 1977-07-26 1985-08-20 Merck & Co., Inc. Prostaglandin antagonists
US4093728A (en) 1977-08-18 1978-06-06 E. R. Squibb & Sons, Inc. Triazoloisoindoles
US4140776A (en) 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4130566A (en) 1977-10-27 1978-12-19 Sumitomo Chemical Company, Limited Process for producing 5-carboxy-2-acetylthiophene
US4127584A (en) 1977-11-11 1978-11-28 Merck & Co., Inc. 2,3-Substituted-1,2,5-thiadiazolium salt antimicrobials
US4159279A (en) 1977-11-23 1979-06-26 Merck & Co., Inc. Nuclear substituted 2-hydroxyphenylmethanesulfamic acids
US4267341A (en) 1977-11-23 1981-05-12 Merck & Co., Inc. Process for preparing 2,3-substituted-1,2,-isothiazolium salt antimicrobials
US4292430A (en) 1977-11-23 1981-09-29 Merck & Co., Inc. 2,3-Substituted-1,2-isothiazolium salt antimicrobials
US4166177A (en) 1977-12-27 1979-08-28 Merck & Co., Inc. Substituted 2,2-dioxo-1,2,3-benzoxathiazines
US4145551A (en) 1978-01-09 1979-03-20 Merck & Co., Inc. Pyrazine-2-carbonyloxyguanidines
US4401669A (en) 1978-01-27 1983-08-30 Merck & Co., Inc. 2,3-Dihydro-substituted-5-benzoyl benzofuran-2-carboxylic acids and their use in treating hypertension
US4189496A (en) 1978-02-16 1980-02-19 Merck & Co., Inc. 2,3-Dihydro-5-thienylmethyl and furylmethyl-6-substituted and 6,7-disubstituted-benzofuran-2-carboxylic acid
US4163781A (en) 1978-04-17 1979-08-07 Merck & Co., Inc. 3-Amino-N-[(phosphonoamino)iminomethyl]-6-halopyrazinecarboxamide compounds, compositions and methods of use
US4156005A (en) 1978-06-21 1979-05-22 Merck & Co., Inc. Derivatives of 1,2-benzisoxazoles
US4394515A (en) 1978-06-23 1983-07-19 Merck & Co., Inc. 10,11-Dihydro-11-oxodibenzo[b,f]thiepin compounds
US4263207A (en) 1978-08-01 1981-04-21 Merck & Co., Inc. 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof
US4190655A (en) 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
US4226867A (en) 1978-10-06 1980-10-07 Merck & Co., Inc. 3,3-Substituted spiro-1,2,4-benzothiadiazines
US4207329A (en) 1978-10-11 1980-06-10 Merck & Co., Inc. Derivatives of glycolic and glyoxylic acid as inhibitors of glycolic acid oxidase
US4178386A (en) 1978-10-11 1979-12-11 Merck & Co., Inc. Inhibitors of glycolic acid oxidase
US4187315A (en) 1978-10-11 1980-02-05 Merck & Co., Inc. N-alkyl(and cycloalkyl)oxamic acid and derivatives as inhibitors of glycolic acid oxidase
US4342782A (en) 1978-11-16 1982-08-03 Merck & Co., Inc. 1-(Substituted-aminoalkoxyphenyl)-2-methylene-1-alkanones, compositions and use thereof
US4390537A (en) 1978-11-16 1983-06-28 Merck & Co., Inc. 1-(Substituted-aminoalkoxyphenyl)-2-methylene-1-alkanones, compositions and use
US4282365A (en) 1978-11-24 1981-08-04 Merck & Co., Inc. Dibenz[b,e]oxepin compounds
US4249021A (en) 1979-02-26 1981-02-03 Merck & Co., Inc. Indanacetic acid compounds
US4224447A (en) 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4246406A (en) 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4221790A (en) 1979-04-16 1980-09-09 Merck & Co., Inc. Substituted 2,2-dioxo-1,2,3-benzoxathiazines
US4233452A (en) 1979-05-03 1980-11-11 Merck & Co., Inc. Derivatives of glycolic and glyoxylic acid as inhibitors of glycolic acid oxidase
US4220654A (en) 1979-06-04 1980-09-02 Merck & Co., Inc. Cyclic imidazole cyanoguanidines
US4256758A (en) 1979-06-11 1981-03-17 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4431660A (en) 1979-06-11 1984-02-14 Merck & Co., Inc. (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith
US4537902A (en) 1979-06-11 1985-08-27 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4237130A (en) 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
US4291050A (en) 1979-06-21 1981-09-22 Merck & Co., Inc. 6,7-Disubstituted-2 or 2,2-substituted-5-substituted-1-indanones
US4237144A (en) 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-2,6,7-trisubstituted-5-acylbenzofurans
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4459422A (en) 1979-08-17 1984-07-10 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4710513A (en) 1979-08-17 1987-12-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4567289A (en) 1979-08-17 1986-01-28 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4375475A (en) 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4377588A (en) 1979-09-11 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4298743A (en) 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4296237A (en) 1979-09-11 1981-10-20 Merck & Co., Inc. 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4379791A (en) 1979-09-11 1983-04-12 Merck & Co., Inc. 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4337354A (en) 1979-10-19 1982-06-29 Merck & Co., Inc. [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives
US4317922A (en) 1979-10-19 1982-03-02 Merck & Co., Inc. [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives
US4356313A (en) 1979-10-19 1982-10-26 Merck & Co., Inc. [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts
US4432992A (en) 1979-11-05 1984-02-21 Merck & Co., Inc. 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4349561A (en) 1979-11-05 1982-09-14 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4448786A (en) 1979-11-05 1984-05-15 Merck & Co., Inc. 4-Naphthyl and substituted naphthyl-3-hydroxy-3-pyrroline-2,5-diones and their use as inhibitors of glycolic acid oxidase
US4260771A (en) 1979-12-20 1981-04-07 Merck & Co., Inc. Interphenylene 9-thia-11-oxo-12-azaprostanoic acid compounds
US4464363A (en) 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
US4428959A (en) 1980-04-04 1984-01-31 Merck & Co., Inc. 4-Alkylsubstituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4362724A (en) 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4309540A (en) 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4356314A (en) 1980-06-30 1982-10-26 Merck & Co., Inc. [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives
US4317822A (en) 1980-07-02 1982-03-02 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-triazin-2-yl)2-pyrazinecarboxamides
US4272537A (en) 1980-07-02 1981-06-09 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(4,4-disubstituted-6-substituted-1,3,5-triazin-2-yl)-2-pyrazinecarboxamides
US4277602A (en) 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4465850A (en) 1980-09-02 1984-08-14 Merck & Co., Inc. Treatment of brain injury due to gray matter edema with (indanyloxy) butanoic acids
US4389417A (en) 1980-09-05 1983-06-21 Merck & Co., Inc. Treatment of gray matter edema
US4394385A (en) 1980-11-21 1983-07-19 Merck & Co., Inc. Treatment of gray matter edema
US4316043A (en) 1980-12-19 1982-02-16 Merck & Co., Inc. [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives
US4336397A (en) 1980-12-29 1982-06-22 Merck & Co., Inc. 2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis
US4337258A (en) 1980-12-29 1982-06-29 Merck & Co., Inc. 2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis
US4428956A (en) 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4431652A (en) 1980-12-29 1984-02-14 Merck & Co., Inc. 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4778897A (en) 1981-02-25 1988-10-18 Merck & Co., Inc. 6H-dibenz[b,e][1,4]oxathiepin compounds
US4582842A (en) 1981-02-25 1986-04-15 Merck & Co., Inc. Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor
US4454132A (en) 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4420615A (en) 1981-08-24 1983-12-13 Merck & Co., Inc. Substituted pyridopyrimidines as gastric secretion inhibitors
US4463208A (en) 1981-12-30 1984-07-31 Merck & Co., Inc. Treatment of gray matter edema
US4425337A (en) 1981-12-30 1984-01-10 Merck & Co., Inc. Adjuvants for rectal delivery of drug
US4952582A (en) 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4594349A (en) 1982-01-04 1986-06-10 Beyer Jr Karl H Hyperuretic agents
US4663322A (en) 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4440740A (en) 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6032714A (ja) 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US4699917A (en) 1983-09-26 1987-10-13 Merck & Co., Inc. Anti-asthmatic tetrazolyl 6H-dibenz-[B,E]-[1,4]-oxathiepin derivatives, compositions, and method of use therefor
US4596821A (en) 1984-05-01 1986-06-24 Merck & Co., Inc. Treatment of gray matter edema with 3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
US4634717A (en) 1984-05-01 1987-01-06 Merck & Co., Inc. Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, useful for treating persons with gray matter edema
US4680414A (en) 1984-05-01 1987-07-14 Merck & Co., Inc. Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
US4605663A (en) 1984-05-01 1986-08-12 Merck & Co., Inc. Use of substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, for treatment of grey matter edema
US4604403A (en) 1984-05-01 1986-08-05 Merck & Co., Inc. Use of substituted-3(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treating grey matter edema
US4605664A (en) 1984-05-01 1986-08-12 Merck & Co., Inc. Use of substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treatment of grey matter edema
US4604394A (en) 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
US4754061A (en) 1985-06-04 1988-06-28 Merck & Co., Inc. Substituted (2,3-dihydro-1-oxo-1H-inden-5-yl)alkanoic acids, their derivatives and their salts
US4579869A (en) 1985-08-02 1986-04-01 Merck & Co., Inc. Substituted [(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]alkanoic acids, their derivatives and their salts
US4604396A (en) 1985-09-26 1986-08-05 Merck & Co., Inc. [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidamides and [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidic acid hydrazides, their derivatives and their salts
US4654365A (en) 1985-09-26 1987-03-31 Merck & Co., Inc. 2,3-dihydro-5-(3-oxo-2-cyclohexen-1-yl)-2-benzofurancarboxylic acids, and their salts useful in the treatment of brain injury
US4719310A (en) 1985-12-23 1988-01-12 Merck & Co., Inc. Ester and amide substituted (2,3-dihydro-4-(3-oxo-1-cyclohexen-1-yl)phenoxy)alkanoic acids and their salts
US4625047A (en) 1985-12-23 1986-11-25 Merck & Co., Inc. Substituted (2,3-dihydro-4-(3-oxo-1-cyclohexen-1-yl)phenoxy) alkanoic acids, their derivatives and their salts
US4731472A (en) 1986-03-03 1988-03-15 Merck & Co., Inc. (5,6-dichloro-3-oxo-9A-propyl-2,3,9,9A-tetrahydrofluoren-7-yl)alkanoic acids and alkanimidamides
US4777281A (en) 1986-03-03 1988-10-11 Merck & Co., Inc. [3,4-dichloro-6,7,8,8a,9,10-hexahydro-6-oxo-8a-substituted-2-phenanthrenyl)oxy]-alkanoic acids and -ethanimidamides
US4835313A (en) 1986-03-03 1989-05-30 Merck & Co., Inc. (5,6-dichloro-3-oxo-9α-propyl-2,3,9,9α-tetrahydrofluoren-7-yl) alkanimidamides
US4751244A (en) 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4699926A (en) 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4731473A (en) 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4675341A (en) 1986-08-13 1987-06-23 Merck & Co., Inc. [(5,6-dichloro-3-oxo-9a-propyl-2,3,9,9a-tetrahydrofluoren-7-yl)oxy]ethanol and its derivatives
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US4769370A (en) 1986-09-24 1988-09-06 Merck & Co., Inc. (1,2-dichloro-8-oxo-5a-substituted-5a,6,7,8-tetrahydrodibenzofuran-3-yl)alkanoic acids and alkanimidamides
US4797391A (en) 1986-09-24 1989-01-10 Merck & Co., Inc. ((5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy)alkanoic acids and alkanimidamides
US4731470A (en) 1986-11-03 1988-03-15 Merck & Co., Inc. [(5,6-dichloro-3-oxo-2,9a-alkano-2,3,9,9a-tetrahydro-1H-fluoren-7-yl)oxy]alkanoic acids and alkanimidamides
US4731471A (en) 1986-11-03 1988-03-15 Merck & Co., Inc. (5,6-dichloro-3-oxo-2,3,9,9a-tetrahydrofluoren-7-yl)-alkanoic acids and alkanimidamides bearing novel functional 9a-substituents
US4782073A (en) 1986-12-24 1988-11-01 Merck & Co., Inc. Amides of [(5,6-dichloro-3-oxo-9-alpha-substituted-2,3,9,9-alpha-tetrahydrofluoren-7-yl-oxyl]acetic acids, and pharmaceutical compositions thereof
US4775695A (en) 1987-06-01 1988-10-04 Merck & Co., Inc. Substituted amidinoalkoxy and amidinoalkylamino indanones and salts thereof
US4771076A (en) 1987-06-01 1988-09-13 Merck & Co., Inc. [(2-substituted 1,2-dihydro-1-oxo-1H-inden-5-yl)oxy]alkanesulfonic acids and salts thereof
US5132296A (en) 1987-08-14 1992-07-21 Cherksey Bruce D Membrane NA+ channel protein and related therapeutic compounds
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
US4894376A (en) * 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5215991A (en) 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5449682A (en) 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
US5182299A (en) 1990-03-19 1993-01-26 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes
AU654979B2 (en) 1990-10-05 1994-12-01 University Of North Carolina At Chapel Hill, The Method of administering amiloride
EP0517573A1 (fr) 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
ES2107698T3 (es) 1993-02-20 1997-12-01 Hoechst Ag Benzoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento, como inhibidores del intercambio celular de na+/h+ o como agente de diagnostico, asi como medicamento que las contiene.
US5384128A (en) 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US5538991A (en) 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5618557A (en) 1994-11-22 1997-04-08 E.R. Squibb & Sons, Inc. Prophylactic treatment of allergic contact dermatitis
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5908611A (en) 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
WO1997009997A1 (en) 1995-09-12 1997-03-20 Genentech, Inc. Cystic fibrosis therapy
US6399585B1 (en) 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
ATE288273T1 (de) 1997-08-29 2005-02-15 Univ North Carolina Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
US6153187A (en) 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
US6159968A (en) 1998-01-15 2000-12-12 University Of Cincinnati Activation of chloride channels for correction of defective chloride transport
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
CA2332540A1 (en) 1998-05-22 1999-12-02 Benjamin R. Yerxa Therapeutic dinucleotide and derivatives
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6264975B1 (en) 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6344475B1 (en) 1998-10-27 2002-02-05 Yale University Conductance of improperly folded proteins through the secretory pathway
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US6331529B1 (en) 1999-02-26 2001-12-18 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
US20040195160A1 (en) 1999-07-12 2004-10-07 Marine Desalination Systems, L.L.C. Hydrate-based reduction of fluid inventories and concentration of aqueous and other water-containing products
US6475509B1 (en) 1999-07-19 2002-11-05 The University Of North Carolina At Chapel Hill Covalent conjugates of sodium channel blockers and active compounds
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
AUPQ344799A0 (en) 1999-10-15 1999-11-11 University Of Sydney, The Treatment of respiratory diseases and infections
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US6204270B1 (en) 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
US20040199456A1 (en) 2000-08-01 2004-10-07 Andrew Flint Method and apparatus for explaining credit scores
AU1529402A (en) 2000-11-20 2002-05-27 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
DE10101440B4 (de) 2001-01-15 2017-10-26 REMS-WERK Christian Föll und Söhne GmbH & Co. Preßzange
US20030135716A1 (en) 2002-01-14 2003-07-17 Gil Vinitzky Method of creating a high performance virtual multiprocessor by adding a new dimension to a processor's pipeline
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US20050227974A9 (en) 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
US6777721B1 (en) * 2002-11-14 2004-08-17 Altera Corporation SCR device for ESD protection
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
JP2007502827A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
PT1663235E (pt) * 2003-08-18 2013-10-29 Parion Sciences Inc Novos bloqueadores dos canais do sódio de pirazinoílguanidina protegida
AU2004264441A1 (en) * 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
US20090253714A1 (en) 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7030717B2 (en) * 2004-05-19 2006-04-18 Soontai Tech Co., Ltd Impedance-matching wave filter
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
CA2575670A1 (en) 2004-08-18 2006-03-02 Michael R. Johnson Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
US20090324724A1 (en) 2004-08-18 2009-12-31 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US8143256B2 (en) 2004-08-18 2012-03-27 Parion Sciences, Inc. Cyclic amide and ester pyrazinoylguanidine sodium channel blockers
JP4964469B2 (ja) 2005-01-14 2012-06-27 ガジック・テクニカル・エンタープライゼス 磁気ヘッド及びディスクをテストするための真空チャック・スピンスタンド
US20070021439A1 (en) 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
WO2007146867A2 (en) 2006-06-09 2007-12-21 Parion Sciences Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
DK2035004T3 (en) 2006-06-09 2013-01-02 Parion Sciences Inc Phenylsubstituerede pyrazinoylguanidin-natriumkanalblokkere med beta-agonistaktivitet
CA2653773A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
CN101534813A (zh) 2006-09-07 2009-09-16 帕里昂科学公司 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
TW200819430A (en) 2006-09-07 2008-05-01 Michael R Johnson Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
MX2009002602A (es) 2006-09-07 2009-05-28 Parion Sciences Inc Metodos para aumentar la hidratacion mucosa y el despeje mucoso mediante tratamiento con bloqueadores de canal de sodio y osmolitos.
US20080293740A1 (en) 2007-04-03 2008-11-27 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders
WO2008124491A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
NZ586940A (en) 2008-02-26 2012-08-31 Parion Sciences Inc Poly aromatic sodium channel blocker compounds comprising both pyrazine and guanidine moieties
US8261047B2 (en) 2008-03-17 2012-09-04 Freescale Semiconductor, Inc. Qualification of conditional debug instructions based on address
WO2009138378A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US20100074881A1 (en) 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
MX2011004374A (es) 2008-10-23 2011-05-23 Vertex Pharma Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011156355A1 (en) 2010-06-09 2011-12-15 Kainos Medicine, Inc. Production method of phenyl guanidine salts and their intermediates
KR20120017648A (ko) 2010-08-19 2012-02-29 삼성전자주식회사 디스플레이장치와, 디스플레이 패널의 구동방법
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9072738B2 (en) 2011-06-27 2015-07-07 Parion Sciences, Inc. Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
TR201809148T4 (tr) 2012-05-29 2018-07-23 Parion Sciences Inc Göz kuruluğu ve diğer mukozal hastalıkların tedavisi için sodyum kanal blokör etkinliğine sahip dendrimer benzeri amino asitler.
WO2014036445A2 (en) 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
AP3872A (en) 2012-11-15 2016-10-31 Bayer Pharma AG 5-Fluoro-n-(pyridin-2-yl) pyridin-2-amine derivatives containing a sulfoximine group
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
MX368243B (es) 2013-08-23 2019-09-25 Parion Sciences Inc Agentes mucolíticos de ditiol.
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers

Also Published As

Publication number Publication date
US20040204425A1 (en) 2004-10-14
WO2003070182A2 (en) 2003-08-28
KR101225201B1 (ko) 2013-01-22
AU2003211135A1 (en) 2003-09-09
US20170267650A1 (en) 2017-09-21
US20070265280A1 (en) 2007-11-15
US20130012692A1 (en) 2013-01-10
US8846688B2 (en) 2014-09-30
JP4557550B2 (ja) 2010-10-06
US20140179625A1 (en) 2014-06-26
US10167266B2 (en) 2019-01-01
EP1485360B1 (en) 2011-08-17
US6858615B2 (en) 2005-02-22
JP2010059210A (ja) 2010-03-18
AU2009225374A1 (en) 2009-11-05
US20030199456A1 (en) 2003-10-23
US8227474B2 (en) 2012-07-24
KR20100134801A (ko) 2010-12-23
EP1485360A2 (en) 2004-12-15
HK1070369A1 (en) 2005-06-17
US20090227530A1 (en) 2009-09-10
US20060142306A1 (en) 2006-06-29
KR101183274B1 (ko) 2012-09-14
PT1485360E (pt) 2011-11-28
US20040229884A1 (en) 2004-11-18
KR20040091064A (ko) 2004-10-27
KR101008728B1 (ko) 2011-01-18
SI1485360T1 (sl) 2012-02-29
US20150376146A1 (en) 2015-12-31
EP1485360A4 (en) 2006-07-05
KR20100134802A (ko) 2010-12-23
CA2476430C (en) 2011-11-08
US7186833B2 (en) 2007-03-06
JP2005530692A (ja) 2005-10-13
US7332496B2 (en) 2008-02-19
US7189719B2 (en) 2007-03-13
AU2009225374B2 (en) 2011-12-22
CA2476430A1 (en) 2003-08-28
US20100144661A1 (en) 2010-06-10
ATE520674T1 (de) 2011-09-15
ES2374130T3 (es) 2012-02-14
US20040198748A1 (en) 2004-10-07
US20040198749A1 (en) 2004-10-07
US20190241528A1 (en) 2019-08-08
US20090062308A1 (en) 2009-03-05
AU2003211135B2 (en) 2009-07-23
DK1485360T3 (da) 2011-12-05
US7192960B2 (en) 2007-03-20
US8198286B2 (en) 2012-06-12
WO2003070182A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
CY1112906T1 (el) Αναστολεις διαυλου νατριου
WO2003070184A3 (en) Sodium channel blockers
WO2005016879A3 (en) Cyclic pyrazinoylguanidine sodium channel blockers
WO2005025496A3 (en) Aliphatic pyrazinoylguanidine sodium channel blockers
CY1107400T1 (el) Συνταγοποιηση κοκκου μοντελουκαστης
CY2015015I1 (el) Παραγωγη τιακουμυκινης
WO2006023617A3 (en) Cyclic amide & ester pyrazinoylguanidine sodium channel blockers
CA2534682A1 (en) Capped pyrazinoylguanidine sodium channel blockers
CY1114638T1 (el) Νεοι παρεμποδιστες διαυλων νατριου καλυμμενης πυραζινοϋλογουανιδινης
NO20091976L (no) Nye forbindelser
UY3441Q (es) Cepillo de dientes
SG145694A1 (en) Novel compounds
WO2006023573A3 (en) Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
DE602004031372D1 (de) Nachweis von staphylococcus
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
DE602004002101D1 (de) Natrium-cyanid-verfahren
DE50309647D1 (de) Ng fibrotischer erkrankungen
UY3455Q (es) Dentifrico
UY3457Q (es) Dentifrico
UY3461Q (es) Dentifrico
CY1114588T1 (el) Αποκλειστες διαυλων νατριου κεκαλυμμενης πυραζινοϋλγουανιδινης
ATE295746T1 (de) Radioaktiv beschichtete stents
DOP2002000329A (es) Composicion solida